Turmeric extract shows promise for PCOS and fatty liver in new trial
NCT ID NCT07278128
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether taking curcumin (from turmeric) daily for 12 weeks could improve cholesterol, blood sugar, hormones, and liver health in women with both PCOS and nonalcoholic fatty liver disease. 74 women participated in a double-blind, placebo-controlled trial. The goal was to find a safer alternative to standard drugs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- curcumin (turmeric extract)
- What this could lead to
- If it works, this could point toward a natural supplement to help manage PCOS and fatty liver disease together.
- What could go wrong
- This is a small, completed Phase 2/3 trial. Curcumin is poorly absorbed, and results may not apply to all women. It is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
74 people
The number who actually took part.
- Started
-
Jun 2024
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: Women of reproductive age from 18 to 45 years old Women with polycystic ovary syndrome and non-alcoholic fatty liver disease Having two of the three Rotterdam criteria including: Having an ultrasound appearance of polycystic ovaries, having serum hyperandrogenism with/without clinical symptoms related to hyperandrogenism such as acne, hirsutism, acanthosis nigricans, etc., having an ovulation disorder and irregular menstrual cycle. Ability to speak and write in Persian Exclusion criteria: -Pregnancy Breastfeeding Using hormonal methods for contraception Having any other diagnosed disease Sensitivity to turmeric History of advanced chronic liver disease Smoking and alcohol use Drug addiction Adrenal hyperplasia that has symptoms similar to polycystic ovary syndrome Kidney failure or any active digestive disorder Other chronic non-metabolic diseases Thyroid disease Hyperprolactinemia
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nonalcoholic fatty liver disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tarbiat Modares university
Tehran, Tehran Province, 1411713116, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brown Fat's hidden role in fatty liver disease under investigation
- Can a single pill tackle both fatty liver and diabetes?
- Could a common b vitamin tame fatty liver?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- Could a daily dose of citrus fiber tame fatty liver inflammation?
- New drug shows promise in shrinking fatty liver